Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Lineage Cell Therapeutics Inc (LCTX)

Lineage Cell Therapeutics Inc (LCTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 212,159
  • Shares Outstanding, K 169,727
  • Annual Sales, $ 4,340 K
  • Annual Income, $ -43,020 K
  • 60-Month Beta 1.89
  • Price/Sales 48.87
  • Price/Cash Flow N/A
  • Price/Book 2.49
Trade LCTX with:

Options Overview Details

View History
  • Implied Volatility 177.33% ( -16.13%)
  • Historical Volatility 72.55%
  • IV Percentile 76%
  • IV Rank 19.14%
  • IV High 806.32% on 04/21/22
  • IV Low 28.49% on 01/20/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 20
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 5,670
  • Open Int (30-Day) 5,718

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.03
  • Number of Estimates 3
  • High Estimate -0.02
  • Low Estimate -0.04
  • Prior Year -0.03
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1000 +13.64%
on 05/16/22
1.3750 -9.09%
on 04/25/22
+0.0700 (+5.93%)
since 04/22/22
3-Month
1.1000 +13.64%
on 05/16/22
1.6600 -24.70%
on 03/28/22
-0.1800 (-12.59%)
since 02/24/22
52-Week
1.1000 +13.64%
on 05/16/22
3.0000 -58.33%
on 06/25/21
-1.1900 (-48.77%)
since 05/24/21

Most Recent Stories

More News
Lineage Cell Therapeutics, Inc. (LCTX) Q1 2022 Earnings Call Transcript

LCTX earnings call for the period ending March 31, 2022.

LCTX : 1.2500 (unch)
Lineage Cell (LCTX) Reports Q1 Loss, Misses Revenue Estimates

Lineage Cell (LCTX) delivered earnings and revenue surprises of -500% and 56.62%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

LCTX : 1.2500 (unch)
NXGN : 17.90 (+1.24%)
Lineage Cell Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating...

LCTX : 1.2500 (unch)
BioCardia, Inc. (BCDA) Reports Q1 Loss, Lags Revenue Estimates

BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of -26.67% and 68.42%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

BCDA : 1.5500 (-8.28%)
LCTX : 1.2500 (unch)
Urogen Pharma (URGN) Reports Q1 Loss, Misses Revenue Estimates

Urogen Pharma (URGN) delivered earnings and revenue surprises of 8.09% and 13.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

URGN : 5.15 (-6.53%)
LCTX : 1.2500 (unch)
Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates

Ultragenyx (RARE) delivered earnings and revenue surprises of -24.43% and 5.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

RARE : 45.80 (-4.46%)
LCTX : 1.2500 (unch)
Lineage Cell Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 12, 2022

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report...

LCTX : 1.2500 (unch)
RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from the...

LCTX : 1.2500 (unch)
Lineage to Present at B. Riley Securities 2022 Neuro & Ophthalmology Virtual Investor Conference on April 27, 2022

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today Brian M. Culley, Lineage’s...

LCTX : 1.2500 (unch)
Lineage Announces a Fifth Cell Therapy Program: Allogeneic Photoreceptor Transplants for the Treatment of Diseases Which May Lead to Blindness

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced a new cell therapy...

LCTX : 1.2500 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Lineage Cell Therapeutics Inc. is a clinical-stage biotechnology company. It focuses on developing and commercializing therapies for the treatment of degenerative diseases primarily in the United States and internationally. The company's lead product candidates include OpRegen, OPC1 and VAC2 which are...

See More

Key Turning Points

3rd Resistance Point 1.3467
2nd Resistance Point 1.3033
1st Resistance Point 1.2767
Last Price 1.2500
1st Support Level 1.2067
2nd Support Level 1.1633
3rd Support Level 1.1367

See More

52-Week High 3.0000
Fibonacci 61.8% 2.2742
Fibonacci 50% 2.0500
Fibonacci 38.2% 1.8258
Last Price 1.2500
52-Week Low 1.1000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar